MUCOEPIDERMOID CARCINOMA
\mjˈuːkə͡ʊpˌɪdəmˌɔ͡ɪd kˌɑːsɪnˈə͡ʊmə], \mjˈuːkəʊpˌɪdəmˌɔɪd kˌɑːsɪnˈəʊmə], \m_j_ˈuː_k_əʊ_p_ˌɪ_d_ə_m_ˌɔɪ_d k_ˌɑː_s_ɪ_n_ˈəʊ_m_ə]\
Sort: Oldest first
-
A tumor of both low- and high-grade malignancy. The low-grade grow slowly, appear in any age group, and are readily cured by excision. The high-grade behave aggressively, widely infiltrate the salivary gland and produce lymph node and distant metastases. Mucoepidermoid carcinomas account for about 21% of the malignant tumors of the parotid gland and 10% of the sublingual gland. They are the most common malignant tumor of the parotid. (From DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p575; Holland et al., Cancer Medicine, 3d ed, p1240)
By DataStellar Co., Ltd
Word of the day
Proto Oncogene Proteins c erbB 2
- cell surface protein-tyrosine kinase that is found to be overexpressed in significant number adenocarcinomas. It has extensive homology can heterodimerize EGF EPIDERMAL GROWTH FACTOR), 3 receptor (RECEPTOR, 3) and the 4 receptor. Activation of erbB-2 receptor occurs during heterodimer formation with a ligand-bound erbB family members. EC 2.7.11.-.